clinical trial · NCT06542731
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Ono Pharmaceutical Co., Ltd.·phase1·active not recruiting·n = 42
Non-small Cell Lung CancerONO-4578ONO-4538DocetaxelRamucirumab
brief summary
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug
started
Jun 1, 2021
primary completion
Sep 12, 2026
completion
Dec 31, 2026
last updated
Aug 7, 2024
official title
Phase 1 Study of ONO-4578 Given as Combinations of ONO-4578, ONO-4538, Docetaxel and Ramucirumab in Subjects With Metastatic Non-small Cell Lung Cancer Who Have Had Disease Progression During or After One Prior First-line Anti-PD-(L) 1 Antibody and Platinum-based Chemotherapy for Advanced/Metastatic Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol